EN DE
Check 35,000+ stocks against 26 valuation models and 37 quality factors
Data-driven stock valuation

Al Hammadi Co (4007) fair value: what the stock is really worth

We calculate from audited financials what Al Hammadi Co is really worth. The fair value tells you whether the price is too high or too low, the quality score (0 to 100) how solid the business behind it is. 26 models, 37 quality factors, updated daily.

  1. Fair value above price? No
  2. Good quality? Yes
  3. Add to watchlist

Healthcare · SA · ISIN SA13J051UJH4

AH Broad data Sep 13, 2026

Al Hammadi Co

4007 · SR

NeutralThe stock looks roughly fairly valued with average quality.

·Fair value 23.54 SAR · Fairly valued (−4%)
!Quality 59/100
!Mixed Growth (revenue 5y +4.5 %/yr)
Solidly profitable · 17.9% net margin (TTM)
Low debt · generates free cash flow
·3.89% dividend yield
Ranks above peers (12/14)
!Moderate moat 56/100
!Weak on valuation: 29 out of 100
!Weak on future: 29 out of 100

What runs behind every stock

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

63.75 SAR 21.49 SAR Fair Value 23.54 SAR May 2021 Sep 2026

White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Sep 13, 2026.

How to read this chart

60‑month range 21.49 SAR – 63.75 SAR · fair‑value band 13.37 SAR – 32.76 SAR · the 24.43 SAR price screens above the 23.54 SAR fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Sep 13, 2026.

Which stocks are undervalued right now? Check free Discover now →

Company profile

Al Hammadi Holding Company, a healthcare group, provides healthcare services in the Kingdom of Saudi Arabia. The company operates through Medical Services and Pharmaceuticals Products segments.

Show more

Al Hammadi Holding Company, a healthcare group, provides healthcare services in the Kingdom of Saudi Arabia. The company operates through Medical Services and Pharmaceuticals Products segments. The company offers inpatient and outpatient hospital services, including accommodation, medical professional services, equipment, radiology, laboratory, and bundled healthcare offerings; and provides medical services. The company was formerly known as Al Hammadi Company For Development and Investment and changed its name to Al Hammadi Holding Company in August 2022. Al Hammadi Holding Company was founded in 1985 and is based in Riyadh, the Kingdom of Saudi Arabia.

Stock analysis

Al Hammadi Co (4007) currently trades at 24.43 SAR, while our model-based Fair Value estimate is 23.54 SAR, implying the stock looks roughly 3.8% fairly valued today.

Show more

Valuation

Bull case: the Growth Earnings group reads highest at a median of 30.33 SAR per share, and 10 of the 26 models we run sit above the 24.43 SAR price.

Bear case: the Asset-Based group reads lowest at 8.40 SAR, and 16 of the 26 models stay below the price. Evidence for this calculation is high.

Scenario range: 13.37 SAR (bear) to 32.76 SAR (bull), the price of 24.43 SAR sits inside it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 59/100 (solid quality), in the Healthcare sector.

Mixed Growth: Revenue is growing, but margins or cash flow do not fully confirm the trend.

Al Hammadi Co reported revenue of 1.2B SAR in FY2025 versus 952M SAR in FY2021, a compound +6.7%/yr. Reported net income was 242M SAR in FY2025, compounding +28.0%/yr from FY2021.

Key figures

Market cap 4.2B SAR (≈ $1.1B) · P/E ratio 17.5 · P/S ratio 3.42 · EPS (TTM) 1.40 SAR · Dividend yield 3.9% · Net margin 19.6% · Return on equity 11.2% · Return on assets (EBIT) 10.8%.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 50 out of 100 (low confidence).

What moves the price

The share trades about 31% below its 52-week high and 6% above its 52-week low, currently below its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at 0% fair-value upside, at −4%, 4007 screens richer than that median.

Fair Value models

Bear 13.37 SAR Fair Value 23.54 SAR Bull 32.76 SAR
Model Each model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model. Based on fiscal year 2025 figures (about 8 months old). Earnings retained since then (0.3168 SAR per share) are deliberately not added. Bear Bear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull Bull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. Evidence Evidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Highest evidence
FCF DCF 8.20 SAR 12.98 SAR 20.19 SAR 79
Growth DCF 8.27 SAR 12.40 SAR 18.20 SAR 78
Owner Earnings 16.19 SAR 25.54 SAR 39.63 SAR 75
All 26 models by family
DCF Models
FCF DCF 8.20 SAR 12.98 SAR 20.19 SAR 79
Owner Earnings 16.19 SAR 25.54 SAR 39.63 SAR 75
5Y Revenue Exit 11.73 SAR 20.23 SAR 31.34 SAR 71
5Y EBITDA Exit 15.79 SAR 27.98 SAR 42.55 SAR 74
5Y P/E Exit 17.18 SAR 30.64 SAR 45.12 SAR 70
10Y Revenue Exit 9.90 SAR 17.28 SAR 27.64 SAR 65
10Y EBITDA Exit 12.88 SAR 22.60 SAR 36.16 SAR 67
10Y P/E Exit 13.75 SAR 24.42 SAR 38.12 SAR 62
Earnings-Based
Graham-Dodd 10.28 SAR 35.24 SAR 47.29 SAR 64
Lynch FV 8.12 SAR 11.59 SAR 15.07 SAR 61
PEG = 1.0 8.12 SAR 11.59 SAR 15.07 SAR 57
EPV 12.82 SAR 14.87 SAR 16.64 SAR 74
Dividend Discount
Gordon GGM 10.97 SAR 21.86 SAR 33.11 SAR 67
DDM Multi-Stage 10.97 SAR 18.64 SAR 23.08 SAR 67
Multiples
P/E Multiple 24.94 SAR 33.26 SAR 41.57 SAR 63
P/S Multiple 19.27 SAR 25.70 SAR 32.12 SAR 58
P/B Multiple 19.27 SAR 25.70 SAR 32.12 SAR 55
EV/EBIT 20.08 SAR 26.83 SAR 33.58 SAR 66
EV/EBITDA 22.35 SAR 29.86 SAR 37.38 SAR 67
EV/Revenue 14.28 SAR 20.47 SAR 26.67 SAR 53
Asset-Based
NCAV (Graham) 6.27 SAR 8.40 SAR 12.53 SAR 54
Growth DCF
Growth DCF 8.27 SAR 12.40 SAR 18.20 SAR 78
Rev-Margin DCF 11.73 SAR 20.09 SAR 29.90 SAR 72
Economic Profit
Residual Income 11.52 SAR 13.17 SAR 20.21 SAR 75
ROIC Compounder 12.91 SAR 16.28 SAR 20.61 SAR 72
Growth Earnings
Growth-Adj P/E 21.23 SAR 30.33 SAR 39.43 SAR 67

Open the full fair value analysis →

Notify me when 4007 reaches fair value

Put 4007 on your watchlist. We get in touch as soon as price and fair value meet or the trend turns.

Set up alert →

Quality Score breakdown

Overall quality 59/100

Of which business quality 57 · Market factors (momentum, volatility) 41

Profitability 48
Margins and returns on capital today
Quality Growth 24
Are margins and returns improving?
Cashflow 44
Earnings quality: real cash, not paper profit
Fin. Strength 77
Balance sheet, leverage, solvency risk
Investment 75
Disciplined investing over empire-building
Low Volatility 91
Calm price path (market factor)
Momentum 27
Price trend over the last 3–12 months (market factor)
52W Momentum 8
Distance to the 52-week high (market factor)
Net Issuance 81
Share count: buybacks or dilution?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality Growth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 64/100
Revenue is growing, but margins or cash flow do not fully confirm the trend.
Revenue growth 1 year
+7.0%
Revenue growth 3 years Measures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+3.2%
Revenue growth 5 years Measures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+4.5%
Revenue growth 13 years Measures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+9.5%
What shareholders gained per year (last 5 years) What the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate.
+23.1%
Earnings growth per share plus dividend.
Earnings per share, growth per year+19.2%
Dividend (yield on the price)3.9%
Pace: 5 vs 10 years Two data points, not a trend model: earnings growth per share over the last 5 fiscal years against the last 10. Labelled "steady" when both rates are within 3 percentage points of each other, otherwise picking up or flattening. Shown only when ten years of history exist.19% vs 7%, picking up
Profit margin 2020 to 2025 Operating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.18% → 21%

Growth Forecast

A lot of optimism in the price
The price assumes more growth than the company has delivered so far and more than analysts expect.
What the price assumes This turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).
+20.4%
Yearly growth needed for the next five years to justify today's price.
What forecasts expect Analysts publish sales forecasts for the next two fiscal years. For the years after that, growth slows evenly to 2 % a year by year ten (2 % is the long-run rate our models use). Projected years are marked as such.
+9.4%
Yearly sales growth analysts expect, extended to five years.
Forecast 2026 (sales)+7.0%
Forecast 2027 (sales)+11.9%
Projected 2028 (sales)+10.7%
Projected 2029 (sales)+9.4%
Projected 2030 (sales)+8.2%

Watch 4007, get fair value alerts →

Compare Al Hammadi Co with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Medical Care Facilities · 255 stocks

Beats the industry median on 13/14 measures
Overall it ranks above its industry peers.
Valuation
Quality Score 59 · Above median
Fair Value upside −3% · Above median
Profitability
Return on equity (TTM) 11% · Above median
Return on assets 5% · Above median
Net margin (TTM) 18% · Top 25%
Operating margin (TTM) 16% · Top 25%
Growth and dividend
Revenue growth 6% · Above median
Dividend yield (TTM) 3.9% · Above median
Balance sheet
Debt / equity 0.08× · Below median

Valuation Multiplesvs Medical Care Facilities median · lower = cheaper

P/E (TTM) 17.5× · Cheaper than median
P/B 0.56× · Cheapest 25%
P/S (TTM) 0.90× · Cheaper than median
P/FCF 9.3× · Pricier than median
EV/EBITDA 3.8× · Cheapest 25%

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)29 · sector 29
FUTURE (revenue growth)29 · sector 27
PAST (return on equity)45 · sector 31
HEALTH (low debt)96 · sector 90
DIVIDEND (yield)78 · sector 42

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Medical Care Facilities stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value
HCA Healthcare, Inc HCA $426.94 $506.40 +19%
Fresenius SE FRE €45.04 €32.15 −29%
Dr. Sulaiman Al Habib Medical Services Group 4013 232.70 SAR 112.37 SAR −52%
IHH Healthcare Berhad, an investment holding company, Q0F 2.67 SGD 1.51 SGD −43%
Tenet Healthcare Corporation THC $263.69 $294.55 +12%
DaVita Inc DVA $181.55 $180.71 +0%
Apollo Hospitals Enterprise Limited APOLLOHOSP ₹8,850 ₹2,955 −67%
Fresenius Medical Care AG FME €38.44 €71.28 +85%
Aier Eye Hospital Group 300015 ¥8.06 ¥10.86 +35%
Max Healthcare Institute Limited MAXHEALTH ₹1,038 ₹284.87 −73%

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend Stocks

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names ⭐ Top Rated 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Cite: Fair Value Calculator (2026). "Al Hammadi Co Fair Value". https://www.fairvalue-calculator.com/stock/4007

Frequently asked questions

Is Al Hammadi Co (4007) overvalued or undervalued?
As of Sep 13, 2026, our model estimates a fair value of 23.54 SAR versus a price of 24.43 SAR, about −4% upside (fairly valued).
What is the fair value of 4007?
Our model-based fair value for Al Hammadi Co is 23.54 SAR (as of Sep 13, 2026), built from audited fundamentals. The current price: 24.43 SAR.
What is the quality score of 4007?
Al Hammadi Co has a Quality Score of 59/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Al Hammadi Co (4007)?
Our model-based price target is the fair value of 23.54 SAR (as of Sep 13, 2026) from 26 valuation models. Cautious scenario 13.37 SAR, optimistic scenario 32.76 SAR. It is a calculation from audited fundamentals, not an analyst target.
What is the Al Hammadi Co stock forecast for 2026?
Our models put fair value at 23.54 SAR, about −4% upside versus a price of 24.43 SAR (fairly valued). Cautious scenario 13.37 SAR, optimistic scenario 32.76 SAR. The calculation is refreshed regularly with new filings.
What is the revenue of Al Hammadi Co (4007)?
Al Hammadi Co reported trailing-twelve-month revenue of about 1.3B SAR (latest available figure, as of Sep 13, 2026).
Does Al Hammadi Co pay a dividend?
Al Hammadi Co currently shows a dividend yield of about 3.89% relative to its recent price (as of Sep 13, 2026).
What growth is priced into Al Hammadi Co (4007)?
For today's price to be fair in a discounted-cash-flow model, Al Hammadi Co would have to grow free cash flow by +20.4 % per year for five years (discount rate 10.3 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 5 years revenue grew +4.5 % per year. As of Sep 13, 2026.
What discount rate (WACC) does the fair value of 4007 use?
Our models discount Al Hammadi Co at 10.3 %: a base by market capitalisation (small), damped by beta 0.01, country premium for Saudi Arabia. The same rate applies in all 26 models.
What is a reverse DCF?
A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For Al Hammadi Co that is +20.4 % per year a year over ten years, using the same discount rate (10.3 %) and the same formula as our fair value.
How much growth has Al Hammadi Co (4007) delivered so far?
Over the past 5 years revenue at Al Hammadi Co grew +4.5 % a year. The price currently implies +20.4 % per year free-cash-flow growth a year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.
How fast is the sector of Al Hammadi Co (4007) growing?
The median revenue growth in the sector is +4.3 % a year. That is the yardstick for the growth priced into Al Hammadi Co (+20.4 % per year a year): it shows whether the expectation is within the usual range or beyond it.
What is the free cash flow yield of Al Hammadi Co (4007)?
The free-cash-flow yield on the price is 3.09 %: that much free cash flow Al Hammadi Co produces per unit of market value. When it exceeds the discount rate of our models (10.3 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.
What is the intrinsic value of Al Hammadi Co (4007)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Al Hammadi Co it is 23.54 SAR per share (as of Sep 13, 2026), against a price of 24.43 SAR. It is the blended result of 26 valuation models (cash flow, earnings, asset, dividend).
Is Al Hammadi Co stock overvalued or undervalued in 2026?
As of Sep 13, 2026, 4007 trades above its calculated fair value: price 24.43 SAR, fair value 23.54 SAR, a gap of about −4% (fairly valued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 4007?
No. The price is what the market pays today (24.43 SAR); the fair value is what the company's own numbers justify (23.54 SAR). For Al Hammadi Co the two are 0.8900 SAR per share apart. That gap is exactly why we show both numbers side by side.
How much is Al Hammadi Co worth?
The market values Al Hammadi Co at about 4.2B SAR (market capitalisation, as of Sep 13, 2026). Per share that is 24.43 SAR; our models calculate a fair value of 23.54 SAR per share.
What do the bullish and bearish scenarios say about 4007?
Our models span a range for Al Hammadi Co: cautious scenario 13.37 SAR, base 23.54 SAR, optimistic 32.76 SAR per share (as of Sep 13, 2026, price 24.43 SAR). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of 4007?
Al Hammadi Co trades at a price-to-earnings ratio of 17.5 (as of Sep 13, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of 23.54 SAR is built from several models across several years. Other multiples: P/B 0.6, P/S 0.9, EV/EBITDA 3.8.
How solid is the balance sheet of Al Hammadi Co (4007)?
Balance-sheet figures for Al Hammadi Co (as of Sep 13, 2026): return on equity 11.2%, debt of 0.08 per unit of equity. They feed the Quality Score of 59/100, which measures business quality independently of the share price.
How far is 4007 from its 52-week high?
Al Hammadi Co trades at 24.43 SAR, about 31% below its 52-week high of 35.37 SAR and 6% above the low of 23.06 SAR (as of Sep 13, 2026). Distance from the high says nothing about value: that is what the fair value of 23.54 SAR is for.
Which stocks are comparable to Al Hammadi Co?
From the same area (Healthcare) we also value HCA Healthcare, Inc, Fresenius SE, Dr. Sulaiman Al Habib Medical Services Group, IHH Healthcare Berhad, an investment holding company,, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Al Hammadi Co stock attractive at the current price?
The data as of Sep 13, 2026: price 24.43 SAR, calculated fair value 23.54 SAR (−4%), Quality Score 59/100, from 26 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of 4007 calculated?
We run Al Hammadi Co through 26 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of 23.54 SAR, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 15.8 % above its aggregate fair value. Al Hammadi Co itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What should I pay attention to with Al Hammadi Co right now?
The price sits close to our fair value, market and models broadly agree here, little valuation tension. A fairly wide model range (13.37 SAR to 32.76 SAR) leaves room in how you read the outcome.
Where does the earnings growth of Al Hammadi Co (4007) come from?
Earnings per share at Al Hammadi Co grew +11.0 % a year from 2014 to 2025. Broken into its drivers: revenue per share +9.9 %, EBIT margin −5.2 %, tax rate +0.2 %, residual (interest, one-offs) +6.4 %. The four rates multiply to the earnings growth rate, they do not add up. Start and end are three-year averages so a single exceptional year does not distort the result.

Key figures of Al Hammadi Co

How large is the market capitalisation of Al Hammadi Co (4007)?
The market capitalisation of Al Hammadi Co is 4.2B SAR (≈ $1.1B). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Al Hammadi Co (4007)?
The price-to-sales ratio of Al Hammadi Co is 3.42 (P/E × margin). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Al Hammadi Co (4007)?
Earnings per share at Al Hammadi Co are 1.40 SAR (price ÷ EPS = P/E 17.5). Earnings per share over the last twelve months: total profit spread across every single share.
What is the dividend yield of Al Hammadi Co (4007)?
The dividend yield of Al Hammadi Co is 3.9% (payout 67.9%). Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.
What is the net margin of Al Hammadi Co (4007)?
The net margin of Al Hammadi Co is 19.6% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Al Hammadi Co (4007)?
The return on equity (ROE) of Al Hammadi Co is 11.2% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Al Hammadi Co (4007)?
On an EBIT basis the return on assets of Al Hammadi Co is 10.8% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Al Hammadi Co (4007)?
The operating margin of Al Hammadi Co is 16.5% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Al Hammadi Co (4007)?
Revenue at Al Hammadi Co is growing +5.7% versus a year earlier (3y avg +3.2%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Al Hammadi Co (4007)?
Earnings per share at Al Hammadi Co are growing −23.9% versus a year earlier. How much earnings per share grew versus a year earlier.
How much net debt does Al Hammadi Co (4007) carry?
The net debt of Al Hammadi Co is 159M SAR (fiscal year 2025, ≈ 1.3 yrs of FCF). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed

Watch Al Hammadi Co in the live analysis

One click puts Al Hammadi Co on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.